Effects of individualized step targets on physical activity in COPD. A randomized study
Data files
Jan 24, 2025 version files 34.55 KB
-
Data3_visit3.csv
3.36 KB
-
Data5_visit2.csv
15.32 KB
-
Data5_visit4.csv
9.82 KB
-
README.md
6.04 KB
Abstract
Background: Improving physical activity (PA) is important for patients with chronic obstructive pulmonary disease (COPD). Goal setting could be one possible measure; however, its effect could not be maintained for more than 6 months.
Objectives: We evaluated the effects of providing an individualized target of step count, which could reflect the disease condition of each patient, on PA after 6 months in patients with COPD.
Methods: We performed a randomized parallel group, open-label study (INTAR-Step study) between the target provision group (Interv) and the usual care group (Cont) and investigated differences in the proportion of subjects who achieved the target and differences in changes in PA parameters and myokines.
Results: A total of 73 patients were analyzed (Interv, n=38; Cont, n=35). The proportion of subjects in the Interv group who achieved their target did not show a significant increase relative to the Cont group (p=0.157). The percentage of the actual step count value to the target value, changes in the step count and the duration of activity at ≥3.0 METs exhibited significant increases in the Interv group. The changes in the GDF-15, FABP-3, and Irisin were also increased in the Interv group. Furthermore, GDF-15 was significantly higher in patients with increased step counts than in those with decreased step counts.
Conclusion: Providing individualized target step count values did not increase the proportion of subjects who achieved their target values, but it increased their step counts after 6 months. GDF-15 may be involved in the increase in the step count.
README: Effects of individualized step targets on physical activity in COPD. A randomized study
https://doi.org/10.5061/dryad.v41ns1s6c
Description of the data and file structure
After obtaining informed consent (visit 1; week –8, permitted between weeks –20 and –4), participants were required to measure patient demographics, post-bronchodilator spirometry, patient-reported outcome measures (PROMs), serum myokines, body composition, chest computed tomography (CT), transdermal advanced glycation end-products (AGEs), and PA using an accelerometer with a recording of a diary for 2 weeks. Eight weeks after visit 1, participants were randomly assigned to the intervention (Interv) group or the control (Cont) group (visit 2; week 0). Subjects in the Interv group were taught the importance of increasing their step counts and were provided with the target step count value and a pedometer, whereas subjects in the Cont group only taught the importance of increasing their step counts (Data3_visit2.csv). Twelve weeks after visit 2 (visit3; week 12, permitted at week 8-19) (Data3_visit3.csv) and 24 weeks after visit 2 (visit 4; week 24, permitted at week 20–40) (Data3_visit4.csv), participants were required to measure their PA using an accelerometer while recording a diary for 2 weeks. At visit 4, participants were also required to measure their demographics, PROMs, body composition, serum myokines, and transdermal AGEs
Files and variables
File: Data5_visit2.csv
Description: Baseline data (at visit 1 and visit 2). This file contains baseline data (visit 1) and randomization results (visit 2).
Variables
Interv: intervention group; Cont, control group
Target value: individual target value of step count
Age: 5, 50-59; 6, 60-69; 7, 70-79; 8, 80-89 years old at the time of consent.
Smoking(pack-years): smoking history, expressed as packs x years.
Housemate(Y/N): Y, subject who lives with other persons; N, subject who lives alone
Occupation(Y/N): Y, subject who has a job; N, subject who has no job or is retired
Sex: binary variable left ambiguous to further de-identify patients
SpO2(%): lowest SpO2 values during six-minute walking test
BP(mmHg): blood pressure. expressed in mmHg
Hight(cm): expressed in cm
Weight(kg): expressed in kg
BMI(kg/m^2): body mass index, expressed in kg/m^2
IC(L): inspiratory capacity, expressed in liter
FEV1(L): forced expiratory volume in one second, expressed in liter
FVC(L): forced vital capacity, expressed in liter
FVC%pred(%): forced vital capacity percent of predicted value, expressed in %
FEV1%pred(%): forced expiratory volume in one second percent of predicted value, expressed in %
FEV1/FVC(%): forced expiratory volume in one second / forced vital capacity, expressed in %
mMRC(point): score of modified Medical Research Council dyspnea scale
CAT(point): score of COPD assessment test
PROMS-D(point): score of patient-reported outcome measures for dyspnea
KCL(point): score of Kihon Checklist
MOCA-J(point): score of Japanese version of the Montreal Cognitive Assessment
AGE: AGE value measured with AGE scanner, AGE200® (Diagnoptics Technologies BV, Netherlands)
Phase A(˚): phase angle measured with bioelectric impedance analysis using a body composition analyzer, InBody S10® (InBody Japan Inc., Tokyo, Japan)
SMI(kg/m^2): smooth muscle index, expressed in kg/m^2
Total PA(METs·h): the total physical activity, calculated as the sum of metabolic equivalents (METs) values (≥3.0 METs) x the time spent (hours)
Step(steps): number of step counts per day
1-1.5METs(min): the duration of physical activity at 1.0-1.5 METs
≥2METs(min): the duration of physical activity at ≥2.0 METs
≥3METs(min): the duration of physical activity at ≥3.0 METs
GDF-15(pg/mL): growth differentiation factor-15, expressed in pg/mL
BDNF(pg/mL): brain-derived neurotrophic factor, expressed in pg/mL
Osteonectin(ng/mL): expressed in ng/mL
FABP-3(pg/mL): fatty acid-binding protein-3, expressed in pg/mL
FSTL-1(pg/mL): follistatin-like protein 1, expressed in pg/mL
Oncostatin M(pg/mL): expressed in pg/mL
FGF21(pg/mL): fibroblast growth factor-21, expressed in pg/mL
Irisin(ng/mL): expressed in ng/mL
Null: data could not be obtained
ND: not detected.
Reasons for “null” data:
Since MoCA-J was set as an optional item, some data became “null”. E00073 could not obtain AGE data due to measurement error. E00028 and E00008 could not perform InBody due to right leg prosthesis and ICD implantation, respectively. E00077 could not fully obtain InBody data (phase angle and SMI) due to measurement error. E00068, and E00067 could not obtain phase angle data because the InBody at the facility did not support phase angle measurement.
File: Data3_visit3.csv
Description: 3-month evaluation (at visit 3). This file contains the data from 3 months after randomization (visit 3).
Variables
- E00071, E00022, and E00031 were excluded at 3-months evaluation (visit 3) because they met exclusion criteria or invalid physical activity data.
- Abbreviations of variables are same as “Baseline data (at visit 1 and visit 2)”.
File: Data5_visit4.csv
Description: 6-month evaluation (at visit 4). This file contains the data from 6 months after randomization (visit 4).
Variables
- 0016, E00056, E00071, E00003, E00074, E00022, and E00031 were excluded at 6-month evaluation (visit 4) because they met exclusion criteria or invalid physical activity data.
- Abbreviations of variables are same as “Baseline data (at visit 1 and visit 2)”.
- Reasons for “null” data:
Since MoCA-J was set as an optional item, some data became “null”. E00028 and E00008 could not perform InBody due to right leg prosthesis and ICD implantation, respectively. E00068, and E00067 could not obtain phase angle data because the InBody at the facility did not support phase angle measurement.
Methods
Recruitment was performed at 5 institutes, including Osaka Metropolitan University, Saga University, Yamaguchi University, Wakayama Medical University, and NHO Wakayama Hospital. Written informed consent was obtained from all of the participants.